← Patent-cliff monitor small molecule ZORYVE ROFLUMILAST
Loss of exclusivity August 2042 latest FDA-listed patent expiry
Drug detail Brand name ZORYVE Active ingredient ROFLUMILAST Strength 0.3% Dosage form FOAM Route TOPICAL Modality Small molecule FDA approval December 2023 Marketing status RX
Listed patents Patent Expires Type 12453721 August 2042 product 12329751 December 2041 use U-3773 11707454 December 2041 use U-3773 11129818 August 2037 use U-3773 12310956 June 2037 use U-4203 12011437 June 2037 product 12016848 June 2037 product 12005052 June 2037 product 12257242 June 2037 product 12336983 June 2037 product 12220409 June 2037 product 12042487 June 2037 product 9884050 June 2037 product 10940142 June 2037 product 11793796 June 2037 product 9907788 June 2037 use U-3773 12390453 June 2037 product 11819496 June 2037 use U-3773 11992480 June 2037 use U-3773 12005051 June 2037 use U-3773
Regulatory exclusivity Code Expires I-969 May 2028 NP December 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.